The KDM2B Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the KDM2B gene in the human non-small cell lung cancer line NCI-H1975. This polyclonal pool contains a heterogeneous mixture of edited alleles, providing a loss-of-function model that retains the genetic diversity inherent to pooled populations. The product is generated through CRISPR/Cas9-mediated gene disruption, enabling researchers to study the consequences of KDM2B ablation without introducing exogenous transgenes or clonal selection artifacts. This format is particularly suitable for experiments where polyclonal representation more accurately reflects the biological variability observed in tumor cell populations.
NCI-H1975 is a widely used human lung adenocarcinoma epithelial cell line established from a metastatic pleural effusion. It harbors endogenous EGFR L858R and T790M mutations, rendering it a clinically relevant model for acquired tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). The L858R mutation confers oncogenic activation of EGFR signaling, while the T790M gatekeeper mutation impairs the binding of first- and second-generation EGFR inhibitors. Consequently, NCI-H1975 cells serve as a platform for investigating mechanisms of TKI resistance, alternative oncogenic signaling, and the influence of epigenetic modifiers like KDM2B on tumor biology in an EGFR-mutant background.
KDM2B, also referred to as FBXL10, is a histone lysine demethylase that specifically removes methyl marks from dimethylated H3K36 (H3K36me2) and, to a lesser extent, trimethylated H3K4 (H3K4me3), thereby regulating chromatin accessibility and transcriptional programs. This enzyme functions both as a catalytic demethylase and as a component of non-canonical polycomb repressive complex 1 (PRC1) through interactions with RNF2, RYBP, BCOR, and PCGF1. KDM2B is transcriptionally activated by upstream factors including MYC, NOTCH1, RELA (a subunit of NF-??B), and HIF1A. It mediates downstream regulation of genes such as the cyclin-dependent kinase inhibitors CDKN2B and CDKN1A, ribosomal protein genes, and HOXA cluster genes. Through these interactions, KDM2B integrates signals from Notch (via NOTCH1/HES1), NF-??B (via RELA/IKBKB), and Wnt (via CTNNB1/TCF4) pathways, with CTNNB1 acting as a direct interaction partner. Its epigenetic activity contributes to the control of cell proliferation, senescence, and stem cell maintenance.
Knockout of KDM2B in NCI-H1975 cells disrupts the delicate balance of histone methylation patterns, potentially altering the expression of genes governed by these converging oncogenic pathways. In the context of EGFR-mutant NSCLC, KDM2B loss may influence the chromatin landscape at promoters and enhancers regulated by Notch and NF-??B signaling, thereby affecting tumor cell phenotypes such as proliferation, apoptosis, and migration. Since CDKN2B and CDKN1A are key mediators of cell cycle arrest, their dysregulation upon KDM2B knockout could modify the cellular response to EGFR-dependent growth signals. Moreover, the interaction with CTNNB1 suggests that KDM2B may modulate Wnt-dependent transcriptional outputs, adding a layer of epigenetic control to ??-catenin-driven gene expression. The polyclonal nature of the knockout population provides a robust system for detecting consistent phenotypic changes without the bias of single-clone selection.
This KDM2B knockout polyclonal cell model is well-suited for a range of advanced research applications in epigenetic regulation of lung cancer biology. It can be employed for functional validation of KDM2B target genes identified by transcriptomic approaches such as RNA-seq, or for chromatin immunoprecipitation (ChIP-qPCR) studies to map histone modification changes at specific loci. The cells are compatible with standard assays including western blotting and RT-qPCR for expression analysis, as well as cell proliferation, apoptosis, and migration assays to assess phenotypic endpoints. Given the EGFR mutant background, the model is particularly valuable for drug sensitivity screening to uncover synthetic lethal interactions or resistance mechanisms involving epigenetic modulators. Researchers may explore the interplay between KDM2B-dependent chromatin regulation and responses to EGFR TKIs or other targeted agents. For further information, please contact Ascent Research.
